Brief: Biosynex's Procisedx Obtains First FDA Approvals

Biosynex SA

02/10/2023 07:10

Oct 2 (Reuters) - Biosynex SA  ALBIO.PA :
    * PROCISEDX OBTAINS FIRST FDA APPROVALS FOR THERAPEUTIC
MONITORING
TESTS FOR BIOLOGICS REMICADE®, HUMIRA® AND THEIR BIOSIMILARS
    * PROCISEDX WILL BEGIN COMMERCIALIZATION ACTIVITIES
IMMEDIATELY
AND PLANS TO SHIP THE FIRST INSTRUMENTS AND KITS EARLY IN THE
FOURTH QUARTER OF 2023
    * THE USE OF PROCISEDX TESTS IS SET TO CHANGE THE STRATEGY
FOR
MONITORING OF BIOLOGICAL DRUGS IN THE UNITED STATES
    * IT PLANS TO OFFER IFX AND ADL ASSAY KITS IN ADDITION TO
THE IFX
AND ADL ASSAY KITS

Source text for Eikon:  ID:nEQ3br8Dda 
Further company coverage:  ALBIO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))